Alkermes (ALKS)


Market Price (11/21/2026): $44.945 | Market Cap: $7.6 BilSector: Health Care | Industry: Pharmaceuticals

Alkermes (ALKS)


Market Price (11/21/2026): $44.945
Market Cap: $7.6 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13%

Low stock price volatility
Vol 12M is 39%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 77x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 31x

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.2%

Key risks
ALKS key risks include [1] declining sales of its core products, Show more.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13%
1 Low stock price volatility
Vol 12M is 39%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
3 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 77x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 31x
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.2%
6 Key risks
ALKS key risks include [1] declining sales of its core products, Show more.

ALKS in ETFs

Weight = ALKS's share of each fund

VTI0.01%
ITOT0.01%
IWM0.27%
IJR0.45%
VB0.09%
XBI1.6%
IJT0.96%
SLYG0.96%
+18 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Up 22.5% from its Oct 14 low to Nov 11, down 6.2% since (S&P 500 down 1.3%)
The stock's run occurred without specific company news. The biggest daily gains on October 19 and November 6 came without company headlines, while on November 11 the market moved higher.

Nov 3: up 1.8% on its earnings report (S&P 500 up 0.3%)
The stock rose after Alkermes plc reported third quarter 2026 financial results, with diluted EPS of $0.09 and revenue of $480 million. The company surpassed Q3 earnings and revenue estimates, with revenue up 22% versus a year earlier.

Show more
Prices as of 11/20/2026

Up 22.5% from its Oct 14 low to Nov 11, down 6.2% since (S&P 500 down 1.3%)
The stock's run occurred without specific company news. The biggest daily gains on October 19 and November 6 came without company headlines, while on November 11 the market moved higher.

Nov 3: up 1.8% on its earnings report (S&P 500 up 0.3%)
The stock rose after Alkermes plc reported third quarter 2026 financial results, with diluted EPS of $0.09 and revenue of $480 million. The company surpassed Q3 earnings and revenue estimates, with revenue up 22% versus a year earlier.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -8.3% change in ALKS stock from 7/31/2026 to 11/20/2026 was primarily driven by a -12.3% change in the company's P/S Multiple.
(LTM values as of)731202611202026Change
Stock Price ($)48.9944.94-8.3%
Change Contribution By: 
Total Revenues ($ Mil)1,6681,7545.2%
P/S Multiple4.94.3-12.3%
Shares Outstanding (Mil)167168-0.5%
Cumulative Contribution-8.3%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/20/2026
ReturnCorrelation
ALKS-8.3% 
Market (SPY)-7.4%36.2%
Sector (XLV)9.5%28.3%

Fundamental Drivers

The 33.3% change in ALKS stock from 4/30/2026 to 11/20/2026 was primarily driven by a 18.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611202026Change
Stock Price ($)33.7144.9433.3%
Change Contribution By: 
Total Revenues ($ Mil)1,4761,75418.8%
P/S Multiple3.84.313.9%
Shares Outstanding (Mil)165168-1.5%
Cumulative Contribution33.3%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/20/2026
ReturnCorrelation
ALKS33.3% 
Market (SPY)-3.5%19.3%
Sector (XLV)22.4%32.2%

Fundamental Drivers

The 46.4% change in ALKS stock from 10/31/2025 to 11/20/2026 was primarily driven by a 29.1% change in the company's P/S Multiple.
(LTM values as of)1031202511202026Change
Stock Price ($)30.7044.9446.4%
Change Contribution By: 
Total Revenues ($ Mil)1,5211,75415.3%
P/S Multiple3.34.329.1%
Shares Outstanding (Mil)165168-1.7%
Cumulative Contribution46.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/20/2026
ReturnCorrelation
ALKS46.4% 
Market (SPY)2.2%27.2%
Sector (XLV)24.9%35.6%

Fundamental Drivers

The 99.8% change in ALKS stock from 10/31/2023 to 11/20/2026 was primarily driven by a 82.6% change in the company's P/S Multiple.
(LTM values as of)1031202311202026Change
Stock Price ($)22.4944.9499.8%
Change Contribution By: 
Total Revenues ($ Mil)1,5911,75410.2%
P/S Multiple2.44.382.6%
Shares Outstanding (Mil)167168-0.8%
Cumulative Contribution99.8%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/20/2026
ReturnCorrelation
ALKS99.8% 
Market (SPY)71.0%26.8%
Sector (XLV)49.6%36.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ALKS Return17%12%14%4%-3%61%142%
Peers Return3%12%40%-2%34%7%126%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
ALKS Win Rate58%58%58%42%50%45% 
Peers Win Rate56%58%56%48%69%50% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
ALKS Max Drawdown-33%-31%-30%-29%-27%-29% 
Peers Max Drawdown-34%-26%-24%-30%-30%-27% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: NBIX, ACAD, N/A, JNJ, LLY. See ALKS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventALKSS&P 500
2025 US Tariff Shock
  % Loss-25.8%-18.8%
  % Gain to Breakeven34.8%23.1%
  Time to Breakeven390 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-24.0%-9.5%
  % Gain to Breakeven31.5%10.5%
  Time to Breakeven70 days24 days
2020 COVID-19 Crash
  % Loss-30.0%-33.7%
  % Gain to Breakeven43.0%50.9%
  Time to Breakeven96 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-36.2%-19.2%
  % Gain to Breakeven56.8%23.8%
  Time to Breakeven2713 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-13.3%-3.7%
  % Gain to Breakeven15.4%3.9%
  Time to Breakeven7 days6 days
2014-2016 Oil Price Collapse
  % Loss-35.0%-6.8%
  % Gain to Breakeven53.9%7.3%
  Time to Breakeven108 days15 days

Compare to NBIX, ACAD, N/A, JNJ, LLY

In The Past

Alkermes's stock fell -25.8% during the 2025 US Tariff Shock. Such a loss loss requires a 34.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventALKSS&P 500
2025 US Tariff Shock
  % Loss-25.8%-18.8%
  % Gain to Breakeven34.8%23.1%
  Time to Breakeven390 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-24.0%-9.5%
  % Gain to Breakeven31.5%10.5%
  Time to Breakeven70 days24 days
2020 COVID-19 Crash
  % Loss-30.0%-33.7%
  % Gain to Breakeven43.0%50.9%
  Time to Breakeven96 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-36.2%-19.2%
  % Gain to Breakeven56.8%23.8%
  Time to Breakeven2713 days105 days
2014-2016 Oil Price Collapse
  % Loss-35.0%-6.8%
  % Gain to Breakeven53.9%7.3%
  Time to Breakeven108 days15 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-25.1%-17.9%
  % Gain to Breakeven33.5%21.8%
  Time to Breakeven161 days123 days
2008-2009 Global Financial Crisis
  % Loss-62.5%-53.4%
  % Gain to Breakeven166.4%114.4%
  Time to Breakeven902 days1085 days

Compare to NBIX, ACAD, N/A, JNJ, LLY

In The Past

Alkermes's stock fell -25.8% during the 2025 US Tariff Shock. Such a loss loss requires a 34.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Alkermes (ALKS)

Alkermes plc (ALKS) is a global biopharmaceutical company dedicated to researching, developing, and commercializing innovative pharmaceutical products. The company focuses on addressing significant unmet medical needs across various therapeutic areas, aiming to improve the lives of patients in the United States, Ireland, and other international markets.

Alkermes has a portfolio of marketed products primarily targeting central nervous system disorders and addiction. Key products include ARISTADA, RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA, all used in the treatment of schizophrenia and bipolar I disorder. VIVITROL is another significant product, addressing alcohol dependence and preventing opioid dependence. Additionally, VUMERITY is marketed for relapsing forms of multiple sclerosis, expanding the company's reach into autoimmune conditions.

Beyond its established product line, Alkermes continues to innovate with a robust development pipeline. Notable candidates include LYBALVI, an oral antipsychotic for schizophrenia and bipolar I disorder, and nemvaleukin alfa, an immuno-oncology agent designed to stimulate anti-tumor immune responses. The company also leverages strategic collaboration agreements, particularly with Janssen Pharmaceutica, to further expand its research, development, and commercialization efforts.

AI Analysis | Feedback

Here are a few analogies for Alkermes (ALKS):

  • Biogen for psychiatric and addiction therapies. (Like Biogen's focus on neuroscience, Alkermes specializes in mental health and addiction treatments.)
  • Vertex Pharmaceuticals for mental health and addiction. (Similar to Vertex's specialization in challenging diseases like cystic fibrosis, Alkermes focuses on complex psychiatric and addiction conditions.)

AI Analysis | Feedback

  • ARISTADA: An intramuscular injectable suspension used for the treatment of schizophrenia.
  • VIVITROL: Used for the treatment of alcohol dependence and the prevention of opioid dependence.
  • RISPERDAL CONSTA: Treats schizophrenia and bipolar I disorder.
  • INVEGA SUSTENNA: Addresses schizophrenia and schizoaffective disorder.
  • XEPLION: Treats schizophrenia and schizoaffective disorder.
  • INVEGA TRINZA: Treats schizophrenia and schizoaffective disorder.
  • TREVICTA: Treats schizophrenia and schizoaffective disorder.
  • VUMERITY: For the treatment of relapsing forms of multiple sclerosis in adults.
  • LYBALVI: An oral atypical antipsychotic drug candidate in development for schizophrenia and bipolar I disorder.
  • nemvaleukin alfa: An engineered fusion protein in development to expand tumor-killing immune cells.

AI Analysis | Feedback

Alkermes (ALKS) sells its pharmaceutical products primarily to other companies.

Based on the provided company description, a major customer and partner company is:

  • Janssen Pharmaceutica (a subsidiary of Johnson & Johnson, NYSE: JNJ). Alkermes has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International for several products, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA.

For its other commercialized products (such as ARISTADA, VIVITROL, and VUMERITY), Alkermes typically sells to pharmaceutical wholesalers and distributors, which then supply pharmacies, hospitals, and healthcare providers. However, specific names of these wholesale customer companies are not provided in the company description.

AI Analysis | Feedback

null

AI Analysis | Feedback

Richard Pops, Chairman and Chief Executive Officer

Richard Pops joined Alkermes as Chief Executive Officer in 1991 and currently serves as Chairman and CEO. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly-traded biopharmaceutical company with over 2,000 employees. He has also served on the boards of directors of other publicly-traded biotechnology companies, including Neurocrine Biosciences, and previously Acceleron Pharma and Epizyme. Mr. Pops is scheduled to retire from his CEO role on July 31, 2026, and will continue to serve as Chairman of the Board and an advisor to the executive team.

Joshua Reed, Chief Financial Officer

Joshua Reed was appointed Chief Financial Officer of Alkermes, effective September 15, 2025. He brings over 30 years of financial leadership experience, with a strong focus on the biotechnology and pharmaceutical sectors. Prior to joining Alkermes, Mr. Reed served as CFO of Omega Therapeutics and Aldeyra Therapeutics. He also spent more than a decade at Bristol Myers Squibb, where he held the position of Vice President and Head of Finance Operations for the U.S. and Puerto Rico, and held roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation.

Blair Jackson, Executive Vice President, Chief Operating Officer

Blair Jackson serves as Alkermes' Executive Vice President, Chief Operating Officer, a position he has held since January 2021. He joined Alkermes in 1999 and has held various scientific and corporate roles within the company. Mr. Jackson is responsible for Alkermes' strategic planning and corporate services, including global operations, quality, information technology, business development, and corporate planning. He is slated to succeed Richard Pops as Chief Executive Officer, effective August 1, 2026. Additionally, he served as interim principal financial officer from February 2024 to September 2025.

C. Todd Nichols, Senior Vice President, Chief Commercial Officer

C. Todd Nichols is the Senior Vice President, Chief Commercial Officer at Alkermes, a role he assumed in May 2020 after joining the company in May 2019 as SVP, Sales & Marketing. He leads the Sales, Marketing, Market Access, and Commercial Operations functions, overseeing the commercial strategy for Alkermes' marketed medicines. Mr. Nichols brings over 20 years of extensive commercial experience in the biopharmaceutical sector, having previously served as Vice President of Marketing and Sales, Inflammation and Immunology at Celgene. His career also includes marketing and sales leadership positions at Biogen, Merck, and Schering-Plough.

Craig Hopkinson, M.D., Executive Vice President, Research & Development and Chief Medical Officer

Dr. Craig Hopkinson serves as Alkermes' Executive Vice President, Research & Development and Chief Medical Officer.

AI Analysis | Feedback

  • Intense Competition and Pricing Pressure: Alkermes operates in the highly competitive Central Nervous System (CNS) therapeutic area, where its proprietary long-acting injectables like ARISTADA, VIVITROL, and LYBALVI face significant rivalry for market share from both branded and generic drug manufacturers. This competitive landscape, coupled with pressure from national payers demanding proof of value for high-cost treatments, can lead to intense pricing battles and erosion of profitability. The acquisition of LUMRYZ for narcolepsy also introduces the company to an area with emerging competition from other OX2R agonists.
  • Regulatory and Clinical Development Challenges: As a biopharmaceutical company, Alkermes is subject to stringent and evolving regulatory approval processes by agencies such as the FDA and their international counterparts. Delays, failures, or adverse decisions in securing regulatory approvals for new or existing products can significantly impact business operations, financial health, and investor confidence. Furthermore, the success of Alkermes' future growth is highly dependent on its research and development pipeline, including candidates like ALKS 2680. Clinical trial failures or setbacks can lead to increased costs and delays, as exemplified by past program cancellations.
  • Dependence on Key Products and Patent Expirations: A substantial portion of Alkermes' revenue is currently reliant on a few key proprietary products, including ARISTADA, VIVITROL, and LYBALVI. While the company has been shifting towards proprietary product sales, the eventual loss of market exclusivity for these or other products, or increased competition, could lead to significant declines in sales. Even recently acquired products, like LUMRYZ, are projected to face sales declines post-2030 due to patent expirations and increased competition.

AI Analysis | Feedback

The increasing market preference and competitive emergence of highly effective oral therapies or less burdensome administration methods for chronic psychiatric conditions, which could diminish the market share of Alkermes' substantial portfolio of long-acting injectable (LAI) products for schizophrenia and bipolar I disorder. Alkermes' own development of LYBALVI, an oral atypical antipsychotic for these same indications, suggests an internal recognition of this potential market shift.

AI Analysis | Feedback

Alkermes plc (ALKS) develops and commercializes pharmaceutical products across various therapeutic areas. The addressable markets for their main products or services are detailed below:

  • ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia:

    The U.S. market for antipsychotics was estimated at $3 billion in 2022, with long-acting injectables (LAIs) representing approximately 20% or $600 million. ARISTADA competes within this broader market.

  • VIVITROL (naltrexone) for the treatment of alcohol dependence and prevention of opioid dependence:

    Alkermes reported net sales of $467 million for VIVITROL in fiscal year 2023. Projections for 2024 are between $470 million and $490 million, and for 2025, between $490 million and $510 million. The Alcohol Use Disorder Market in the seven major markets (7MM: United States, EU4, UK, and Japan) was valued at approximately $1,106 million in 2025 and is projected to reach $3,489 million by 2034. The U.S. market size was approximately $1,106 million in 2025. The global naltrexone and buprenorphine market size was estimated at $4.17 billion in 2024 and is projected to reach $9.80 billion by 2033, growing at a CAGR of 9.25%. North America held the largest share of 39.4% in 2024.

  • RISPERDAL CONSTA (risperidone) for the treatment of schizophrenia and bipolar I disorder:

    The global market size for RISPERDAL CONSTA was estimated at $3.2 billion in 2022, with a projected Compound Annual Growth Rate (CAGR) of approximately 4.5% from 2023-2028. North America accounts for about 50% of these sales. The broader global antipsychotic drugs market size was valued at $18.51 billion in 2025 and is projected to grow to $27.48 billion by 2034, with North America dominating with a 52.32% share in 2025.

  • INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA (paliperidone palmitate long-acting injectables) for the treatment of schizophrenia and schizoaffective disorder:

    The global schizophrenia treatment market was approximately $4.6 billion in 2022, with injectable antipsychotics accounting for roughly 20% of sales. INVEGA SUSTENNA and its related formulations collectively had global sales exceeding $3 billion in 2022. The U.S. market size for antipsychotics was estimated at $3 billion in 2022, with long-acting injectables (LAIs) representing roughly 20% ($600 million). The total Schizophrenia Market Size in the 7MM was approximately $7,972.0 million in 2022, and in the US, it was approximately $5,749.0 million in 2022. The global schizophrenia market size was valued at approximately $8,000 million in 2024, with the U.S. market at nearly $6 billion in 2024.

  • VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults:

    The global multiple sclerosis drugs market size was valued at $21.07 billion in 2025 and is projected to grow to $53.20 billion by 2034, at a CAGR of 11.08%. North America dominated this market with a 48.51% share in 2025. The global multiple sclerosis therapeutics market size reached $27.42 billion in 2024 and is expected to reach $46.22 billion by 2033, growing at a CAGR of 6.1%. North America holds the largest revenue share of 43.17% in 2024. The Multiple Sclerosis Treatment Market in the 7MM was valued at approximately $20 billion in 2024, and the U.S. market size was approximately $16 billion in 2024.

  • LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and bipolar I disorder:

    LYBALVI was approved in June 2021 and commercially available in the U.S. since October 2021. The global antipsychotic drugs market size was valued at $18.51 billion in 2025 and is projected to grow to $27.48 billion by 2034. North America dominated with a 52.32% share in 2025. The global antipsychotic drugs market was valued at $18.04 billion in 2023 and is expected to reach around $37.40 billion by 2032. The total Schizophrenia Market Size in the 7MM was approximately $7,972.0 million in 2022, and in the U.S. was approximately $5,749.0 million in 2022. The global schizophrenia market size was valued at approximately $8,000 million in 2024, with the U.S. market at nearly $6 billion in 2024.

  • nemvaleukin alfa, an engineered fusion protein for solid tumors:

    Nemvaleukin alfa is being developed for solid tumors, including mucosal melanoma. The global cancer immunotherapy market was valued at $125.7 billion in 2023 and is estimated to grow at a 9.3% CAGR from 2024 to 2032, reaching $277.4 billion.

AI Analysis | Feedback

Alkermes (ALKS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product advancements:

  1. Continued Growth of Key Proprietary Neuroscience Products: Alkermes anticipates sustained revenue growth from its established proprietary products, including ARISTADA for schizophrenia, VIVITROL for alcohol and opioid dependence, and LYBALVI for schizophrenia and bipolar I disorder. In 2025, the proprietary product portfolio grew 9% year over year, with LYBALVI showing particularly strong growth. The company's 2026 guidance projects proprietary product net sales of $1.52 billion to $1.6 billion, demonstrating continued confidence in these core assets.
  2. Integration and Expansion of LUMRYZ Following the Avadel Acquisition: The recent acquisition of Avadel Pharmaceuticals, completed in February 2026, is a significant strategic move that introduces LUMRYZ into Alkermes' commercial portfolio. This acquisition accelerates Alkermes' entry into the commercial sleep medicine market and is expected to be a substantial new revenue stream. LUMRYZ generated $279 million in net sales in 2025 and is projected to contribute $350 million to $370 million in 2026, with further growth anticipated in the narcolepsy and idiopathic hypersomnia markets.
  3. Advancement and Potential Launch of Alixorexton (ALKS 2680): Alixorexton, an investigational orexin-2 receptor agonist for narcolepsy and idiopathic hypersomnia, is considered a transformative opportunity for Alkermes. The company plans to enter Phase 3 studies following a rigorous Phase 2 program and recently granted FDA breakthrough therapy designation. This asset is expected to significantly enhance long-term growth and market entry into new areas within central nervous system disorders.
  4. Expansion of the Orexin Portfolio: Beyond alixorexton, Alkermes is progressing other orexin 2 receptor agonists in its pipeline, including ALKS 7290 for ADHD and ALKS 4510 for fatigue in neurodegenerative disorders. Both are advancing toward Phase 2 trials in 2026, indicating a broader strategic focus on the orexin system to drive future revenue streams.

AI Analysis | Feedback

Share Repurchases

  • Alkermes announced a share repurchase program in February 2024, authorizing the repurchase of up to $400 million of its shares.
  • In 2024, the company repurchased approximately 7.9 million ordinary shares for a total of $200 million under this program.
  • As of September 30, 2024, $200 million remained authorized for future share repurchases, with no shares repurchased in 2025.

Outbound Investments

  • In February 2026, Alkermes completed the acquisition of Ireland-based Avadel Pharmaceuticals for a total transaction value of approximately $2.1 billion. This acquisition was financed using approximately $775 million of cash from the balance sheet and $1.525 billion in term loans due in 2031. The acquisition adds Lumryz to Alkermes' commercial portfolio, accelerating its entry into the sleep medicine market.
  • The company completed the separation of its former oncology business into an independent, publicly-traded company, Mural Oncology plc, in November 2023.

Capital Expenditures

  • Alkermes expects to spend $40 million to $50 million on capital expenditures in 2026. These expenditures are anticipated to support strategic initiatives, including advancing its pipeline programs.

Better Bets vs. Alkermes (ALKS)

Peer Outperformance in Pharmaceuticals

ALKS has outperformed 85% of its 60 Pharmaceuticals peers over 5Y. Pharmaceuticals ranks 7th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Pharmaceuticals constituents that ALKS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
84%
of 70 industry peers · 59.4% return
3Y
72%
of 65 industry peers · 89.1% return
5Y
85%
of 60 industry peers · 108.0% return
No Pharmaceuticals peer with a comparable growth profile has beaten ALKS by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is ALKS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 17.3%74.7%198.5% CAH 523% · MCK 396% · COR 198%
Health Care Services 20 30.7%20.5%14.0% RDNT 146% · HIMS 100% · DGX 92%
Managed Health Care 8 60.1%-12.7%-9.2% OSCR 140% · HQY 54% · ELV 2%
Health Care Facilities 26 13.2%13.0%-10.4% THC 240% · NHC 211% · EHC 187%
Health Care Equipment 50 -2.1%6.7%-19.0% GKOS 393% · UFPT 319% · TMDX 274%
Health Care Supplies 11 19.9%-4.3%-41.8% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals ← 61 -16.1%-0.2%-42.0% LQDA 1178% · KNSA 670% · XERS 648%
Life Sciences Tools & Services 110 -25.7%-28.8%-76.5% AXGN 471% · MEDP 169% · NTRA 165%
Biotechnology 370 -35.9%-45.4%-85.2% ELVN 1310% · DNTH 1164% · TRVI 1159%
Health Care Technology 23 -26.4%-56.9%-86.5% VEEV -13% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ALKSNBIXACADINDVJNJLLYMedian
NameAlkermes Neurocri.Acadia P.N/A Johnson .Eli Lilly 
Mkt Price44.94151.0017.01-270.551,346.12151.00
Mkt Cap7.515.32.9-651.91,200.615.3
Rev LTM1,7543,7021,202-99,33586,4623,702
Op Inc LTM91910122-25,52544,315910
FCF LTM2271,03786-19,59511,6891,037
FCF 3Y Avg34469096-19,1005,283690
CFO LTM2431,06698-26,15930,6451,066
CFO 3Y Avg380726166-25,17017,580726

Growth & Margins

ALKSNBIXACADINDVJNJLLYMedian
NameAlkermes Neurocri.Acadia P.N/A Johnson .Eli Lilly 
Rev Chg LTM15.3%38.0%14.8%-7.8%45.5%15.3%
Rev Chg 3Y Avg3.7%27.8%24.9%-5.9%39.4%24.9%
Rev Chg Q21.8%41.2%22.8%-5.9%38.6%22.8%
QoQ Delta Rev Chg LTM5.2%9.7%5.6%-1.4%8.5%5.6%
Op Inc Chg LTM-74.6%64.4%29.6%-7.9%67.9%29.6%
Op Inc Chg 3Y Avg-31.4%42.5%62.1%-4.4%68.3%42.5%
Op Mgn LTM5.2%24.6%10.2%-25.7%51.3%24.6%
Op Mgn 3Y Avg16.5%23.8%10.4%-25.4%43.7%23.8%
QoQ Delta Op Mgn LTM-3.4%0.7%2.6%--1.1%1.5%0.7%
CFO/Rev LTM13.9%28.8%8.1%-26.3%35.4%26.3%
CFO/Rev 3Y Avg24.4%24.6%16.3%-27.1%25.7%24.6%
FCF/Rev LTM13.0%28.0%7.2%-19.7%13.5%13.5%
FCF/Rev 3Y Avg22.1%23.3%9.7%-20.6%6.3%20.6%

Valuation

ALKSNBIXACADINDVJNJLLYMedian
NameAlkermes Neurocri.Acadia P.N/A Johnson .Eli Lilly 
Mkt Cap7.515.32.9-651.91,200.615.3
P/S4.34.12.4-6.613.94.3
P/Op Inc82.716.924.0-25.527.125.5
P/EBIT77.019.024.0-34.827.127.1
P/E-21,495.721.88.1-40.543.521.8
P/CFO31.114.430.1-24.939.230.1
Total Yield-0.0%4.6%12.3%-4.4%2.8%4.4%
Dividend Yield0.0%0.0%0.0%-2.0%0.5%0.0%
FCF Yield 3Y Avg6.7%5.1%3.5%-4.0%0.6%4.0%
D/E0.20.00.0-0.10.00.0
Net D/E0.1-0.0-0.3-0.00.00.0

Returns

ALKSNBIXACADINDVJNJLLYMedian
NameAlkermes Neurocri.Acadia P.N/A Johnson .Eli Lilly 
1M Rtn3.4%6.9%-15.8%-5.0%6.1%5.0%
3M Rtn-7.0%-1.0%-42.3%-0.6%7.4%-1.0%
6M Rtn22.1%-3.6%-19.4%-16.7%26.7%16.7%
12M Rtn59.4%8.6%-25.7%-36.2%29.8%29.8%
3Y Rtn89.2%37.8%-24.2%-93.4%131.7%89.2%
1M Excs Rtn5.0%8.6%-13.0%-4.3%6.4%5.0%
3M Excs Rtn-4.9%1.8%-39.6%-2.7%11.2%1.8%
6M Excs Rtn22.9%-2.9%-18.6%-17.4%27.5%17.4%
12M Excs Rtn45.0%-2.3%-38.0%-24.9%17.4%17.4%
3Y Excs Rtn39.2%-28.5%-89.0%-33.3%68.7%33.3%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA214755  LUMRYZsodium oxybatefor suspension, extended release50120232.2%-15.1%-7.8%8.1%68.8%
NDA213378  LYBALVIolanzapinetablet528202137.2%-0.9%34.7%29.3%113.2%
NDA209830  ARISTADA INITIO KITaripiprazole lauroxilsuspension, extended release62920183.1%-30.8%-45.2%-54.3%17.5%
NDA207533  ARISTADAaripiprazole lauroxilsuspension, extended release1005201525.2%-39.2%-22.8%-13.2%-19.1%
NDA021897  VIVITROLnaltrexonefor suspension, extended release4132006-24.0%-26.7%-29.6%-49.4%120.1%
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA214755  LUMRYZsodium oxybatefor suspension, extended release50120232.2%-15.1%-7.8%8.1%68.8%
NDA213378  LYBALVIolanzapinetablet528202137.2%-0.9%34.7%29.3%113.2%
NDA209830  ARISTADA INITIO KITaripiprazole lauroxilsuspension, extended release62920183.1%-30.8%-45.2%-54.3%17.5%
NDA207533  ARISTADAaripiprazole lauroxilsuspension, extended release1005201525.2%-39.2%-22.8%-13.2%-19.1%
NDA021897  VIVITROLnaltrexonefor suspension, extended release4132006-24.0%-26.7%-29.6%-49.4%120.1%

Clinical Pipeline

Drug CandidateIndicationPhase 3 TrialsEst. Primary Completion
OLZ/SAM (olanzapine and samidorphan)Pediatric schizophrenia and bipolar I disorder2Sep 2026
ALKS 2680Narcolepsy and idiopathic hypersomnia4May 2027
Active Phase 3 studies led by the company. Source: ClinicalTrials.gov · Updated 8/28/2026

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Developing, manufacturing and commercializing medicines designed to help people living with complex1,4761,5581,6631,112 
License revenue    4
Manufacturing and royalty revenues    542
Product sales, net    627
Research and development revenue    1
Total1,4761,5581,6631,1121,174


Net Income by Segment
$ Mil2025202420232022
Developing, manufacturing and commercializing medicines designed to help people living with complex242367356-158
Total242367356-158


Price Behavior

Price Behavior
Market Price$44.94 
Market Cap ($ Bil)7.5 
First Trading Date07/16/1991 
Distance from 52W High-18.6% 
   50 Days200 Days
DMA Price$43.69$41.42
DMA Trenddownup
Distance from DMA2.9%8.5%
 3M1YR
Volatility32.5%39.4%
Downside Capture106.3640.57
Upside Capture105.5391.58
Correlation (S&P 500)29.9%29.0%
ALKS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.660.690.750.300.780.63
Up Beta-0.28-0.55-0.37-0.231.730.63
Down Beta-1.28-1.77-1.210.160.180.57
Up Capture276%162%136%82%79%43%
Bmk +ve Days12182862130427
Stock +ve Days12213162121369
Down Capture64%159%175%12%54%82%
Bmk -ve Days10253664121325
Stock -ve Days10223364129375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALKS
ALKS56.9%39.4%1.22-
Sector ETF (XLV)18.4%17.1%0.8037.3%
Equity (SPY)5.2%14.4%0.1129.3%
Gold (GLD)-13.9%29.3%-0.5217.7%
Commodities (DBC)28.2%21.5%1.05-6.9%
Real Estate (VNQ)8.6%14.3%0.3325.2%
Bitcoin (BTCUSD)-32.4%43.7%-0.784.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALKS
ALKS15.1%37.0%0.46-
Sector ETF (XLV)7.5%15.4%0.2935.8%
Equity (SPY)9.6%17.4%0.3928.2%
Gold (GLD)13.1%19.3%0.534.8%
Commodities (DBC)6.6%19.6%0.22-0.5%
Real Estate (VNQ)0.5%19.0%-0.0828.9%
Bitcoin (BTCUSD)-0.7%51.4%0.1710.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALKS
ALKS-2.0%40.2%0.08-
Sector ETF (XLV)11.4%16.8%0.5539.4%
Equity (SPY)14.1%18.1%0.6635.6%
Gold (GLD)10.4%16.6%0.501.4%
Commodities (DBC)7.2%18.2%0.3111.6%
Real Estate (VNQ)5.9%20.7%0.2428.4%
Bitcoin (BTCUSD)56.2%66.3%0.968.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity19.6 Mil
Short Interest: % Change Since 101520263.2%
Average Daily Volume1.7 Mil
Days-to-Cover Short Interest11.2 days
Basic Shares Quantity167.9 Mil
Short % of Basic Shares11.7%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/20261.8%2.9% 
7/28/2026-4.2%-6.1%-6.7%
5/5/20266.1%3.8%25.1%
2/25/2026-7.0%-12.5%-12.0%
10/28/20254.3%1.5%-2.5%
7/29/20253.3%1.9%10.8%
5/1/20256.3%5.6%6.4%
2/12/20254.8%12.1%5.2%
...
SUMMARY STATS   
# Positive131311
# Negative111112
Median Positive6.0%3.5%8.4%
Median Negative-5.3%-6.1%-6.0%
Max Positive16.3%15.4%27.0%
Max Negative-12.7%-14.3%-27.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/3/20261.8%2.9% 
7/28/2026-4.2%-6.1%-6.7%
5/5/20266.1%3.8%25.1%
2/25/2026-7.0%-12.5%-12.0%
10/28/20254.3%1.5%-2.5%
7/29/20253.3%1.9%10.8%
5/1/20256.3%5.6%6.4%
2/12/20254.8%12.1%5.2%
10/24/2024-3.6%-5.5%-0.5%
7/24/20246.0%10.5%13.0%
5/1/2024-2.2%0.2%-5.4%
2/15/202416.3%3.3%2.7%
10/25/2023-7.4%-4.5%3.6%
7/26/2023-2.6%-7.5%-9.5%
4/26/2023-7.0%-6.6%-3.8%
2/16/20234.4%1.4%-3.6%
11/2/20223.5%-0.3%8.4%
7/27/2022-5.3%-12.8%-14.2%
4/27/202211.9%6.9%6.3%
2/16/202214.9%3.5%11.1%
10/27/2021-9.1%-5.7%-27.4%
7/28/20216.8%15.4%27.0%
4/28/2021-3.2%-0.9%-0.8%
2/11/2021-12.7%-14.3%-15.3%
SUMMARY STATS   
# Positive131311
# Negative111112
Median Positive6.0%3.5%8.4%
Median Negative-5.3%-6.1%-6.0%
Max Positive16.3%15.4%27.0%
Max Negative-12.7%-14.3%-27.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202607/28/202610-Q
03/31/202605/05/202610-Q
12/31/202502/25/202610-K
09/30/202510/28/202510-Q
06/30/202507/29/202510-Q
03/31/202505/01/202510-Q
12/31/202402/12/202510-K
09/30/202410/24/202410-Q
06/30/202407/24/202410-Q
03/31/202405/01/202410-Q
12/31/202302/21/202410-K
09/30/202310/25/202310-Q
06/30/202307/26/202310-Q
03/31/202304/26/202310-Q
12/31/202202/16/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/03/202610-Q
06/30/202607/28/202610-Q
03/31/202605/05/202610-Q
12/31/202502/25/202610-K
09/30/202510/28/202510-Q
06/30/202507/29/202510-Q
03/31/202505/01/202510-Q
12/31/202402/12/202510-K
09/30/202410/24/202410-Q
06/30/202407/24/202410-Q
03/31/202405/01/202410-Q
12/31/202302/21/202410-K
09/30/202310/25/202310-Q
06/30/202307/26/202310-Q
03/31/202304/26/202310-Q
12/31/202202/16/202310-K
09/30/202211/02/202210-Q
06/30/202207/27/202210-Q
03/31/202204/27/202210-Q
12/31/202102/16/202210-K
09/30/202110/27/202110-Q
06/30/202107/28/202110-Q
03/31/202104/28/202110-Q
12/31/202002/11/202110-K
09/30/202010/29/202010-Q
06/30/202007/29/202010-Q
03/31/202004/29/202010-Q
12/31/201902/13/202010-K

Insider Activity

Updated 11/3/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell1103202646.172,03593,95610,127,528Form
2Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell1002202641.032,03483,4559,083,550Form
3Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell903202648.012,03497,65210,726,490Form
4Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell901202646.999,000422,8743,072,368Form
5Nichols, Christian ToddSVP, Chief Commercial OfficerDirectSell817202649.237,576372,9375,030,560Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell1103202646.172,03593,95610,127,528Form
2Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell1002202641.032,03483,4559,083,550Form
3Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell903202648.012,03497,65210,726,490Form
4Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell901202646.999,000422,8743,072,368Form
5Nichols, Christian ToddSVP, Chief Commercial OfficerDirectSell817202649.237,576372,9375,030,560Form
6Snyderman, Nancy Lynn MD DirectSell803202650.3544,4722,239,076775,107Form
7Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell803202648.589,000437,2203,370,918Form
8Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell803202648.582,03498,81210,952,652Form
9Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell706202654.032,034109,89712,291,285Form
10Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell701202651.519,000463,6213,780,518Form
11Wright, Christopher I DirectSell612202645.102,00090,2001,158,168Form
12Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell604202643.052,03487,5649,881,008Form
13Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell601202641.679,000375,0443,224,916Form
14Parisi, Samuel JosephVP, Finance (Interim PAO)DirectSell529202642.3616,217687,007326,918Form
15Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell504202633.202,03467,5297,687,726Form
16Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell501202633.409,000300,5602,718,026Form
17Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell406202634.572,03470,3158,075,275Form
18Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell401202635.519,000319,6043,032,300Form
19Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell304202629.762,03460,5327,012,230Form
20Parisi, Samuel JosephVP, Finance (Interim PAO)DirectSell304202629.296,890201,808226,031Form
21Nichols, Christian ToddSVP, Chief Commercial OfficerDirectSell304202630.006,000180,0003,293,070Form
22Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell304202629.729,000267,4852,656,695Form
23Gaffin, David JosephEVP, CLO, Alkermes, Inc.DirectSell304202629.292,03459,5766,961,061Form
24Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell202202633.939,000305,3841,959,211Form
25Cooke, Shane DirectSell202202634.5761,2002,115,6733,586,411Form
26Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell102202628.004,000112,0001,728,720Form
27Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell1205202530.003,748112,4471,972,325Form
28Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell1201202529.304,000117,2001,926,182Form
29Hopkinson, Craig CEVP R&D, Chief Medical OfficerDirectSell1103202530.389,000273,4422,118,869Form

Investor Activity (13F)

Updated Nov 21, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Commodore Capital LP$148.5 Mil8.6%36ADD +18.3%13F
Prosight Management, LP$18.2 Mil3.0%46New13F
Spruce Street Capital LP$11.2 Mil2.7%28New13F
Atle Fund Management AB$8.2 Mil2.7%39Hold13F
BVF Inc/Il$70.7 Mil2.3%41New13F
Eagle Health Investments LP$8.4 Mil1.8%26ADD +191.8%13F
Tetragon Partners GP Ltd$5.7 Mil1.1%38ADD +13.2%13F
Frazier Life Sciences Management, L.P.$24.8 Mil0.6%38Hold13F
Avoro Capital Advisors LLC$42.4 Mil0.4%30TRIM -14.3%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
BVF Inc/Il$70.7 Mil2.3%41New13F
Prosight Management, LP$18.2 Mil3.0%46New13F
Spruce Street Capital LP$11.2 Mil2.7%28New13F
Eagle Health Investments LP$8.4 Mil1.8%26ADD +191.8%13F
Commodore Capital LP$148.5 Mil8.6%36ADD +18.3%13F
Tetragon Partners GP Ltd$5.7 Mil1.1%38ADD +13.2%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avoro Capital Advisors LLC$42.4 Mil0.4%30TRIM -14.3%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Commodore Capital LP$148.5 Mil8.6%36ADD +18.3%13F
BVF Inc/Il$70.7 Mil2.3%41New13F
Avoro Capital Advisors LLC$42.4 Mil0.4%30TRIM -14.3%13F
Frazier Life Sciences Management, L.P.$24.8 Mil0.6%38Hold13F
Prosight Management, LP$18.2 Mil3.0%46New13F
Spruce Street Capital LP$11.2 Mil2.7%28New13F
Eagle Health Investments LP$8.4 Mil1.8%26ADD +191.8%13F
Atle Fund Management AB$8.2 Mil2.7%39Hold13F
Tetragon Partners GP Ltd$5.7 Mil1.1%38ADD +13.2%13F
Core Cache Last Updated: 11/20/2026